By Connor Hart
Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer.
The drug, Opdualag, didn't meet its primary endpoint of recurrence-free survival when used as an additional treatment for patients with completely resected stage III-IV melanoma.
Vice President Jeffrey Walch, Opdualag global program lead, said Thursday that patients whose tumors are completely resected, or surgically removed, may not have enough antitumor T cells left for the drug to have its maximal effect.
"Opdualag remains a standard of care in the first-line treatment of unresectable or metastatic melanoma," he said, "and we continue to explore its potential across tumor types, including in non-small cell lung cancer."
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
February 13, 2025 17:42 ET (22:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。